Premarket Stock Movers — August 6, 2026: Why WYHG, PAVS, ENSC, CELZ & MGRX Are Surging

WYHG — Wing Yip Food Holdings Group Ltd (+123.4%)

Wing Yip Food Holdings Group is surging +123.4% to $7.64 in premarket trading this morning, on volume of 24,641,969 shares — vs. a 20-day average of just 50,933. That's roughly 484× its normal daily activity before the opening bell has even rung. When volume dwarfs the average by that magnitude, it signals a market-moving event rather than ordinary price noise.

Why it's moving: No specific catalyst headline is on file for WYHG as of this writing. The only recent SEC filing is a routine 6-K from July 22 flagged as a neutral foreign-event disclosure. With no confirmed news and negligible short interest (just 66,040 shares short, or 1.5 days to cover), a squeeze does not explain this move either — the squeeze score sits at just 13/100. The catalyst is unclear; this appears to be a momentum-driven, volume-fueled spike, and traders should treat it with extreme caution. Moves of this size without an identifiable news driver frequently reverse sharply once the regular session opens.

Technical picture: Going into this morning, WYHG's daily chart showed an inverted hammer candlestick — a pattern that can signal a potential reversal after a downtrend but requires bullish follow-through confirmation. RSI was at 45 (neutral), ADX at 24 (trend not yet established), and the moving-average stack was mixed. The stock sits 48.1% below its 52-week high, indicating it remains in a significant longer-term downtrend. The RS rating is a strong 98, reflecting this premarket burst more than underlying trend health. StockSetups gave it a conviction score of 62/100, a grade of B, and a trend-template score of 6 — a moderate setup at best heading into today.

PAVS — Paranovus Entertainment Technology Ltd. (+88.1%)

Paranovus Entertainment Technology is up +88.1% to $9.33 premarket, on 21,126,355 shares traded — vs. a 20-day average of 1,070,772, roughly 20× normal volume before the open. The stock gapped slightly positive (+1.8%) into yesterday's close and is now exploding further this morning.

Why it's moving: The most recent filing on record is a 6-K filed August 5 (foreign-event, neutral) on SEC EDGAR — and there's also an NT 20-F filed July 31, a late-filing notification (flagged bearish) indicating Paranovus missed the deadline for its annual report. No specific catalyst headline is available. With a free float of only 40.8% — meaning fewer than half of outstanding shares are freely tradeable — even a moderate surge in buying interest can produce outsized price moves. However, the squeeze score is just 6/100 with only 14,924 shares short, so a short squeeze is not the driver.

Technical picture: The prior-day chart showed a bullish MA stack and a strong ADX of 61, suggesting a well-established trend with real momentum heading into this morning. RSI was at 57 — healthy, not overbought. StockSetups placed PAVS in a non-signal lane but gave it a conviction score of 72/100 and a grade B, with a technical rank of 82 — among the stronger setups in today's scan. The stock is still 33.2% below its 52-week high, so the premarket pop is coming from a depressed base. The NT 20-F late-filing flag is worth watching; regulatory and reporting issues can create additional volatility.

ENSC — Ensysce Biosciences, Inc. (+73.7%)

Ensysce Biosciences is spiking +73.7% to $0.64 premarket on 1,911,476 shares — well below its 20-day average of 16,435,648, meaning today's premarket print is actually lighter-than-normal volume for this name. Ensysce trades under $1, putting it firmly in the micro-cap penny-stock category. A short-sale restriction (SSR) is active this morning, which means regulators have placed a curb on certain short-selling in the stock due to its prior-day decline.

Why it's moving: This one has a clear, confirmed catalyst. According to reporting from Investing.com, Yahoo Finance, and Stock Titan, Ensysce has completed its acquisition of Cy Biopharma and simultaneously raised $21.5 million in financing, part of a package that could total up to $77 million in private financing. Adding to the story, a Stock Titan headline notes that the deal brings an FDA Orphan Drug-designated therapy for complex regional pain syndrome into Ensysce's pipeline — a meaningful regulatory designation that can accelerate review and provide market exclusivity. Acquisition announcements paired with capital raises are classic binary catalysts in the biotech space: they can signal a company pivoting toward growth, but they also often come with dilution risk from new share issuance.

Technical picture: Heading into this morning, ENSC's chart carried significant technical weakness — RSI at 68 (elevated), MA stack mixed, ADX at just 21, and the stock sitting a brutal 85.8% below its 52-week high. StockSetups rated it a conviction score of 18/100 and a grade D, with a trend-template score of just 2. The RS rating of 3 confirms it has been a persistent underperformer. This is a news-driven spike in a technically broken name — the fundamental catalyst may be real, but the chart context and near-zero conviction score mean the technical setup offers little support on its own. The SSR adds complexity for short sellers but does not prevent all short activity.

CELZ — Creative Medical Technology Holdings, Inc. (+73.2%)

Creative Medical Technology Holdings is surging +73.2% to $1.18 premarket on a staggering 120,851,475 shares — vs. a 20-day average of just 209,855, or roughly 575× average daily volume. This is the highest relative volume of today's five movers by a wide margin. The company has a market cap of only $2.5 million, placing it among the smallest names on US exchanges.

Why it's moving: No specific company-level catalyst is confirmed. The most relevant recent filing is an S-3 shelf registration filed July 24, followed by a 424B3 resale prospectus on August 3 — both are capital-raising mechanisms. A shelf registration (or "shelf offering") allows a company to sell shares to the market over time, which is typically dilutive to existing shareholders. Benzinga flagged CELZ among health-care stocks moving in Wednesday's after-market session, but no specific news event is identified. Without a confirmed catalyst, this looks like a momentum and volume-driven move in an extremely thin, micro-cap name.

Technical picture: The prior-day chart showed a tweezer bottom candlestick — a pattern that can hint at a short-term reversal after sustained selling (learn more in our guide to Tweezer Tops & Bottoms). However, nearly every other technical signal is bearish: RSI at 31 (near oversold), MA stack bearish, ADX at 22, the stock 87.8% below its 52-week high, technical rank of just 5, and a conviction score of 0/100 — the lowest possible — with a grade D and trend-template score of 0. Short interest is minimal (76,263 shares, 0.1 days to cover), so squeeze dynamics are not at play. With a near-zero conviction score, a resale shelf filing, and no confirmed news, this is one of the riskiest names on this morning's list.

MGRX — Mangoceuticals, Inc. (+35.1%)

Mangoceuticals is up +35.1% to $0.59 premarket on 21,795,016 shares, slightly below its 20-day average of 31,032,239. A short-sale restriction (SSR) is active. Despite its Healthcare sector classification, Mangoceuticals is pursuing a significant corporate transformation that is squarely behind this morning's move.

Why it's moving: The catalyst is well-documented. According to Benzinga, Yahoo Finance, GlobeNewswire, and The Globe and Mail, Mangoceuticals' planned merger partner — Nuclea Energy — has executed an MOU (Memorandum of Understanding) with the Utah Office of Energy Development to explore a Morpheus test-reactor site. This is a meaningful milestone in the proposed deal. Additionally, Mangoceuticals itself was granted a 180-day extension by Nasdaq to meet its listing compliance requirements, buying the company time to complete the Nuclea merger. Multiple 425 merger-related filings and 8-K event filings over the past week confirm the deal is actively progressing. A Benzinga headline noted the stock jumped over 49% in after-hours trading on August 5 — this premarket move is an extension of that surge.

Technical picture: Heading into today, MGRX's daily chart shows a mixed MA stack, RSI at 49 (neutral), ADX at 28, and the stock sitting 84.1% below its 52-week high. StockSetups placed it in a non-signal lane with a conviction score of 49/100, a grade C, and a trend-template score of 3 — modest but not the weakest setup here. The squeeze score is 15/100 with 207,868 shares short and only 0.3 days to cover, so a squeeze isn't driving this. The SSR flag means the stock already fell significantly on a prior day; the current move is entirely news- and deal-driven. Merger timelines frequently shift, and Nasdaq compliance extensions are not guarantees of success.

The bottom line

This morning's five biggest premarket gainers are a concentrated mix of micro-cap momentum names and genuine news catalysts. ENSC has the clearest fundamental driver — a completed acquisition with fresh capital. MGRX is riding real merger-deal news. WYHG, PAVS, and CELZ are moving on massive relative volume with limited or no confirmed catalysts, making them especially high-risk.

A few reminders before the open:

• Premarket prices are not final prices. Liquidity is thin before 9:30 AM ET, spreads are wide, and moves can reverse sharply once the regular session opens and institutional volume kicks in.
• Chasing extended gainers is high-risk. Stocks that double or triple in premarket frequently give back a significant portion of those gains — sometimes within the first hour of trading.
• Low-float and micro-cap names amplify both gains and losses. A low float means fewer shares are available to trade, so even modest buying (or selling) pressure can move the price dramatically in either direction.
• Short-sale restrictions (SSR on ENSC and MGRX) signal prior-day weakness, not strength — always understand what brought a stock to this point.
• None of this is financial advice. Do your own research, size positions appropriately, and know your exit before you enter.

StockSetups scans the full US universe of ~12,300 stocks every premarket morning — detecting patterns, scoring conviction, and surfacing the names worth watching before the bell rings. Check yesterday's Top Stock Movers recap from August 5 to see how these setups were building heading into today.